NCT07337681Not yet recruiting
Wearable Technology-Supported Exercise Program for Fatigue and Quality of Life in Pediatric Cancer Patients (WE-EX PedsCa)
Effect of a Wearable Technology-Supported Exercise Program on Fatigue and Health-Related Quality of Life in Pediatric Cancer Patients: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 13 Jan 2026
Brief summary (registry, in English)
Children and adolescents receiving cancer treatment often experience fatigue, reduced physical activity, and decreased quality of life. Although exercise has been shown to reduce these problems, maintaining regular and safe physical activity during cancer treatment can be difficult due to treatment side effects, safety concerns, and limited access to supervised programs. This study aims to evaluate the feasibility, safety, and effectiveness of a wearable technology-supported exercise program on fatigue and health-related quality of life in pediatric cancer patients aged 13 to 18 years. Participants will be randomly assigned to either an intervention group or a control group. The intervention group will participate in an 8-week structured exercise program delivered through a mobile application, including video-guided exercise sessions performed three times per week and monitored continuously using a wearable activity tracker. The control group will receive standard care and will wear the activity tracker for passive monitoring only. Fatigue and quality of life will be assessed at baseline, mid-intervention, and after completion of the program. Physical activity, heart rate, sleep patterns, and adherence to the exercise program will be objectively monitored using wearable devices. The findings from this study are expected to provide evidence on whether a digitally delivered, wearable-supported exercise program is a feasible and beneficial approach to improving well-being in children and adolescents undergoing cancer treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 4 Jan 2026
- Start date
- Mar 2026
- Primary completion date
- Apr 2026
- Lead sponsor
- Istanbul University
- Diseases
- Childhood cancers
- NCT number
- NCT07337681
What you commit to
- Study type: Interventional
- Planned participants: 50
- From Mar 2026 to the primary completion date, Apr 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of acute infection, uncontrolled cardiac or pulmonary disease, respiratory failure, or uncontrolled hypertension.
- Severe neurological, psychiatric, or musculoskeletal conditions that limit safe participation in exercise.
- Persistent thrombocytopenia (\<10,000/µL) or known coagulation disorders.
- Uncontrolled seizure disorders.
- Any medical or psychological condition deemed by the treating physician to contraindicate exercise participation or compromise study procedures.
Other
- Central nervous system metastases.
Who the study is looking for
- Aged 13 to 18 years.
- Diagnosed with cancer and followed at a pediatric hematology-oncology clinic.
- Currently receiving active cancer treatment and has completed at least one cycle of chemotherapy.
- Clinically stable and medically cleared by the treating physician to participate in low-to-moderate intensity exercise.
- Able to understand instructions and communicate verbally.
- Willing to participate in at least 75% of the prescribed exercise sessions.
- Written informed consent obtained from a parent or legal guardian and assent obtained from the participant.
Age in the registry: 13 years to 18 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.